GlobeNewswire Inc.··NaAtea's AT-587 Shows Promise as Potential First HEV Treatment in Preclinical Study
Atea's AT-587 shows promise as first potential HEV treatment, demonstrating 30-150x greater antiviral activity than existing agents in preclinical studies. Phase 1 trials expected mid-2026.
AVIRPhase 1 clinical trialHepatitis E Virus